Endometriosis is a common estrogen-dependent disorder. C-fos and c-jun are early transcription factors probably related to estradiol-dependent cell proliferation. C-fos gene expression is higher in endometriotic implants compared to normal endometrium and the distribution of c-Fos protein is higher in the stroma of endometriotic tissue. C-Jun expression is also more abundant in ectopic endometrial tissue. These findings point to an increased estrogen signaling in endometriosis and suggest that c-fos and c-jun could be potential targets to emerging treatments designed to affect selectively the endometriotic tissue, such as tissue-specific gene therapy.
CastroA., JohnsonM.C., AnidoM., CortinezA., GablerF., VegaM.. Role of nitric oxide and bcl-2 family genes in the regulation of human endometrial apoptosis.Fertil Steril2002; 78: 587–95.
3.
GompelA., SabourinJ.C., MartinA.. Bcl-2 expression in normal endometrium during the menstrual cycle.Am J Pathol1994; 144: 1195–1202.
4.
CritchleyH.O., TongS., CameronS.T., DrudyT.A., KellyR.W., BairdD.T.. Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo.J Reprod Fertil1999; 115: 389–95.
5.
EissaS., AbuS.M., el SharkawyT.. Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies.Clin Biochem1997; 30: 209–14.
6.
SembaK., KamataN., ToyoshimaK., YamamotoT.. A v-erbB-related proto-oncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.Proc Natl Acad Sci U S A1985; 82: 6497–6501.
7.
EjskjaerK., SorensenB.S., PoulsenS.S., MogensenO., FormanA., NexoE.. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle.Mol Hum Reprod2005; 11: 543–51.
8.
WangD.P., FujiiS., KonishiI.. Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta.Virchows Arch A Pathol Anat Histopathol1992; 420: 385–93.
9.
BrummC., RiviereA., WilckensC., LoningT.. Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri.Virchows Arch A Pathol Anat Histopathol1990; 417: 477–84.
10.
CzerwenkaK., LuY., HeussF.. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria.Int J Gynecol Pathol1995; 14: 98–106.
11.
BircanS., EnsariA., OzturkS., ErdoganN., DundarI., OrtacF.. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.Pathol Oncol Res2005; 11: 32–39.
12.
OdomL.D., BarrettJ.M., PantazisC.G., StoddardL.D., McDonoughP.G.. Immunocytochemical study of ras and myc proto-oncogene polypeptide expression in the human menstrual cycle.Am J Obstet Gynecol1989; 161: 1663–8.
JohnsonM.C., TorresM., AlvesA.. Augmented cell survival in eutopic endometrium from women with endometriosis: expression of c-myc, TGF-beta1 and bax genes.Reprod Biol Endocrinol2005; 3: 45.
15.
ChinenovY., KerppolaT.K.. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity.Oncogene2001; 20: 2438–52.
16.
Boettger-TongH.L., MurthyL., StancelG.M.. Cellular pattern of c-fos induction by estradiol in the immature rat uterus.Biol Reprod1995; 53: 1398–1406.
17.
KirklandJ.L., MurthyL., StancelG.M.. Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus.Endocrinology1992; 130: 3223–30.
18.
PapaM., MezzogiornoV., BrescianiF., WeiszA.. Estrogen induces c-fos expression specifically in the luminal and glandular epithelia of adult rat uterus.Biochem Biophys Res Commun1991; 175: 480–5.
19.
ReisF.M., MaiaA.L., RibeiroM.F., SpritzerP.M.. Progestin modulation of c-fos and prolactin gene expression in the human endometrium.Fertil Steril1999; 71: 1125–32.
20.
ReisF.M., RibeiroM.F., SpritzerP.M.. Regional localization of immunoreactive c-fos and prolactin in human endometrium during the normal menstrual cycle.Gynecol Obstet Invest1999; 47: 120–4.
21.
SalmiA., AmmalaM., RutanenE.M.. Proto-oncogenes c-jun and c-fos are down-regulated in human endometrium during pregnancy: relationship to oestrogen receptor status.Mol Hum Reprod1996; 2: 979–84.
22.
DuboisD.H., SimmenR.C., FlissA., SmithL.C., BazerF.W.. Expression of c-fos in porcine endometrium during the estrous cycle and early pregnancy.Biol Reprod1993; 49: 943–50.
23.
WeiszA., RosalesR.. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor.Nucleic Acids Res1990; 18: 5097–106.
24.
SalmiA., CarpenO., RutanenE.. The association between c-fos and c-jun expression and estrogen and progesterone receptors is lost in human endometrial cancer.Tumour Biol1999; 20: 202–11.
25.
FujimotoJ., HoriM., IchigoS., MorishitaS., TamayaT.. Clinical implication of fos and jun expressions and protein kinase activity in endometrial cancers.Eur J Gynaecol Oncol1995; 16: 138–46.
26.
FujimotoJ., HoriM., IchigoS., MorishitaS., TamayaT.. Estrogen induces expression of c-fos and c-jun via activation of protein kinase C in an endometrial cancer cell line and fibroblasts derived from human uterine endometrium.Gynecol Endocrinol1996; 10: 109–18.
27.
SalmiA., HeikkilaP., LintulaS., RutanenE.M.. Cellular localization of c-jun messenger ribonucleic acid and protein and their relation to the proliferation marker Ki-67 in the human endometrium.J Clin Endocrinol Metab1998; 83: 1788–96.
28.
LiZ.L., AbeH., UekiK., KumagaiK., ArakiR., OtsukiY.. Identification of c-Jun as bcl-2 transcription factor in human uterine endometrium.J Histochem Cytochem2003; 51: 1601–9.
29.
MorishitaS., NiwaK., IchigoS.. Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens.Cancer Lett1995; 97: 225–31.
30.
ShaulianE., KarinM.. AP-1 in cell proliferation and survival.Oncogene2001; 20: 2390–400.
31.
CroweD.L., BrownT.N., KimR., SmithS.M., LeeM.K.. A c-fos/estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines.Moll Cell Biol Res Commun2000; 3: 243–8.
32.
MorschD.M., CarneiroM.M., LeckeS.B., AraújoF.C., CamargosA.F., ReisF.M., SpritzerP.M.. c-fos gene and protein expression in pelvic endometriosis: a local marker of estrogen action.J Mol Histol2009. Feb 8 [Epub ahead of print].
33.
PanH., ShengJ.Z., TangL., ZhuR., ZhouT.H., HuangH.F.. Increased expression of c-fos protein associated with increased matrix metalloproteinase-9 protein expression in the endometrium of endometriotic patients.Fertil Steril2008; 90: 1000–7.
34.
HastingsJ.M., JacksonK.S., MavrogianisP.A., FazleabasA.T.. The estrogen early response gene FOS is latered in a baboon model of endometriosis.Biol Reprod2006; 75: 176–82.
35.
Ohlsson TeagueE.M., Van der HoekK.H., Van der HoekM.B.. MicroRNA-regulated pathways associated with endometriosis.Mol Endocrinol2009; 23: 265–75.
36.
BarlowD., KennedyS.. Endometriosis: new genetic approaches and therapy.Annu Rev Med2005; 56: 345–56.
FedeleL., SomiglianaE., FrontinoG., BenagliaL., ViganoP.. New drugs in development for the treatment of endometriosis.Expert Opin Investig Drugs2008; 17: 1187–202.
39.
OthmanE.E., SalamaS., IsmailN., Al-HendyA.. Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells.Fertil Steril2007; 88: 462–71.
40.
OthmanE.E., ZhuZ.B., CurielD.T., KhatoonN., SalemH.T., KhalifaE.A., Al-HendyA.. Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells.Am J Obstet Gynecol2008; 199: e1–6.
41.
AshidaR., TominagaK., SasakiE.. AP-1 and colorectal cancer.Inflammopharmacology2005; 13: 113–25.
42.
BonovichM., OliveM., ReedE., O'ConnellB., VinsonC.. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.Cancer Gene Ther2002; 9: 62–70.
43.
HoltJ.T., ArteagaC.B., RobertsonD., MosesH.L.. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA.Hum Gene Ther1996; 7: 1367–80.
44.
ArteagaC.L., HoltJ.T.. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice.Cancer Res1996; 56: 1098–1103.
45.
ChastelC., JiricnyJ., JaussiR.. Activation of stress-responsive promoters by ionizing radiation for deployment in targeted gene therapy.DNA Repair (Amst)2004; 3: 201–15.
46.
ZhangL., LiX., ZhaoM., HeP., YuW., DongJ., LiuG., LiC., ShiX.. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy.Exp Eye Res2006; 83: 1405–11.
